Stay updated on Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedWording updated to clarify that PubMed publications are auto-filled and may not be about the study, and the page revision is now v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedRemoval of the funding lapse banner regarding government funding and NIH Clinical Center operations; core trial information remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check49 days agoChange DetectedNo significant additions or deletions were detected on the page; the content remains focused on study details and eligibility criteria.SummaryDifference0.4%

- Check70 days agoChange DetectedSummary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%

- Check78 days agoChange DetectedUpgrade applied: version updated from v3.0.2 to v3.1.0. No other substantive content changes detected.SummaryDifference0.1%

- Check92 days agoChange DetectedUpdated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.2%

Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.